Device Trial Radar · NCT05451862
Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma.
Last checked: Nov 20, 2026Latest source record: Aug 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
6
Actual
Start
Aug 21, 2023
Primary completion
May 27, 2025
Study completion May 27, 2025
Sponsor
- Lead sponsor
- Terumo Europe N.V.Public (4543.T)
- Sponsor type
- Industry
- First posted
- Jul 11, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
166Ho-TARE is a promising modality for the treatment of HCC, given the unique characteristics of holmium, allowing careful patient selection and personalized dosimetry treatment planning. Further clinical evidence is needed to evaluate the safety and efficacy of 166Ho-TARE in the treatment of HCC patients with limited tumor burden, well preserved liver function and performance status and ineligible for liver transplantation and/or liver resection. This study will also provide further evidence on the dose-response relationship of 166Ho-TARE in (early) HCC.
Conditions
- Hepatocellular Carcinoma
Interventions
Holmium-166 treatmentDevice
Implantation into hepatic tumors by delivery via the hepatic artery for the treatment of unresectable HCC liver tumors.
Holmium-166 work-upDevice
Evaluation of lung-shunt, extrahepatic deposition and intrahepatic distribution of intra-arterially injected microspheres for patients that are eligible for TARE treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- confirmed Objective Response Rate (ORR) by localized mRECISTTime frame: 5 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Universitätsklinikum Augsburg
Augsburg, Germany
LMU Klinikum
Munich, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.